Iovance Biotherapeutics, Inc. IOVA Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s change in AP?
- Iovance Biotherapeutics, Inc. (IOVA) reported change in AP of $15.89M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s change in AP changed year-over-year?
- Iovance Biotherapeutics, Inc.'s change in AP increased by 674.3% year-over-year, from $2.05M to $15.89M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s change in AP?
- Over 3 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s change in AP has grown at a -1.5% compound annual growth rate (CAGR), from $6.98M to -$6.66M.
- What does change in AP mean?
- Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.